MedDataX Logo

Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

NCT ID: NCT00339001

Last Updated: 2006-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-30

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinopathy of Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erythropoietin and early iron supplements

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all premature infants with birth weight of 1250 grams or less

Exclusion Criteria

* none
Minimum Eligible Age

2 Weeks

Maximum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheba Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacob Kuint, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neonatal Department, Sheba Medical Center

Ramat Gan, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacob Kuint, MD

Role: CONTACT

[email protected]
972-3-5303030 ext. 2227

Irit Eisen, MD

Role: CONTACT

972-3-5303030 ext. 2227

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacob Kuint, MD

Role: primary

[email protected]
972-3-5303030 ext. 2227

Irit Eisen, MD

Role: backup

972-3-5303030 ext. 2227

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SHEBA-06-4128-JK-CTIL

Identifier Type: -

Identifier Source: org_study_id